3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiol Therapeutics stock.
Is cardiol Therapeutics a strong buy?
Cardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Will cardiol Therapeutics stock go up?
Will Cardiol Therapeutics stock price grow / rise / go up? Yes. The CRTPF stock price can go up from 3.410 USD to 4.348 USD in one year.
Why is cardiol stock dropping?
Cardiol Therapeutics Inc.'s shares sank Wednesday after the clinical-stage biotechnology company priced a roughly $50 million equity raising aimed at advancing research and development programs and additional product development. The offering is expected to close on or about Friday, the company said.3 Nov 2021
Should I sell my CRDL stock?
(CRDL-T) Rating. Stockchase rating for Cardiol Therapeutics INc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Is cardiol stock a good buy?
Cardiol Therapeutics has received a consensus rating of Buy.
Is CRDL a good buy?
Out of 2 analysts, 2 (100%) are recommending CRDL as a Strong Buy, 0 (0%) are recommending CRDL as a Buy, 0 (0%) are recommending CRDL as a Hold, 0 (0%) are recommending CRDL as a Sell, and 0 (0%) are recommending CRDL as a Strong Sell. What is CRDL's earnings growth forecast for 2022-2024?
What does cardiol therapeutics do?
Cardiol Therapeutics Inc. is a life sciences company. The Company focuses on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. Cardiol Therapeutics serves patients in Canada.